<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03493997</url>
  </required_header>
  <id_info>
    <org_study_id>MISTIC</org_study_id>
    <nct_id>NCT03493997</nct_id>
  </id_info>
  <brief_title>Multicentre International STudy for the Prevention With Ialuril® of Radio-induced Cystitis (MISTIC)</brief_title>
  <acronym>MISTIC</acronym>
  <official_title>An Investigative, Randomized, Open, Pilot Study to Assess the Tolerability, Safety and Efficacy of HAcid/CS Intravesical Instillations Plus an Oral Combination of Curcumin,Quercetin, HA and CS in Prevention of Radiation Induced Cystitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Study Group for Urogenital Diseases, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Study Group for Urogenital Diseases, Italy</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is randomized and it will be conducted in the field of routine clinical practice. A
      total of 100 consecutive patients planned to receive radiotherapy for prostate cancer will be
      enrolled.

      The patients will enter the study as controls (50 patients that won't receive any
      experimental IMP) or as treated-group (50 patients that will be also treated with the
      experimental IMPs, Ialuril® and Ialuril® Soft Gels) according to a predefined,
      centre-specific randomization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Radiotherapy will last for 6 weeks. During planning of treatment, regimen and average dose to
      the whole bladder will be recorded to assess the impact of EBRT on urinary symptoms.

      The treated-group will receive also intravesical Ialuril® weekly for 6 weeks (in the 24 hours
      before every radiation therapy weekly schedule), plus oral treatment with Ialuril® Soft Gels
      capsules (1 capsule twice a day after meals, at a distance of 12 hours, for 12 weeks).

      The control-group will receive radiotherapy only for 6 weeks.

      The Primary Objective is to assess the tolerability and safety of HA-CS intravesical
      instillations (Ialuril®) plus an oral combination of curcumin, quercetin, HA and CS (Ialuril®
      Soft Gels) in male patients undergoing radiotherapy for prostate cancer The efficacy of the
      treatment will be evaluated at the end of the study once received all the crfs.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 4, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of patients</measure>
    <time_frame>12 months</time_frame>
    <description>The rate of patients who stopped treatment with intravesical or oral Ialuril due to intollerance or adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>comparative analysis of score between the two groups through ICIQ</measure>
    <time_frame>12 months</time_frame>
    <description>comparative analysis of score between the two groups (active arm vs. no drug arm)following questionnaires scores.
Questionnaires:
• ICIQ-Male Lower Urinary Tract Symptoms (ICIQ-MLUTS) questionnaire and bladder diary - Scale: Never - Occasionally
Sometimes - Most of the time - All of the time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comparative analysis of score between the two groups through EPIC</measure>
    <time_frame>12 months</time_frame>
    <description>comparative analysis of score between the two groups (active arm vs. no drug arm)following questionnaires scores.
Expanded Prostate Cancer Index Composite (EPIC) - Urinary Domain Scale :From 1 to 5 ( 1 smallest, 5 highest)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comparative analysis of score of QOL</measure>
    <time_frame>12 months</time_frame>
    <description>comparative analysis of score between the two groups (active arm vs. no drug arm)following questionnaires scores.
EQ-5D-5L (QoL) -
Scale:
I am not anxious or depressed I am slightly anxious or depressed I am moderately anxious or depressed I am severely anxious or depressed I am extremely anxious or depressed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comparative analysis of score between the two groups through IPSS</measure>
    <time_frame>12 months</time_frame>
    <description>comparative analysis of score between the two groups (active arm vs. no drug arm)following questionnaires scores.
IPSS Scale: 0 to 5 (0 worst - 5 best)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Radiotherapy+Ialuril®+Ialuril Soft Gels®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy+Ialuril®+Ialuril Soft Gels®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiotherapy only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiotherapy only</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Radiotherapy+IAluril®+Ialuril Soft Gels®</intervention_name>
    <description>Radiotherapy+IAluril®+Ialuril Soft Gels®</description>
    <arm_group_label>Radiotherapy+Ialuril®+Ialuril Soft Gels®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy only</intervention_name>
    <description>Radiotherapy only</description>
    <arm_group_label>Radiotherapy only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male patients planned to receive primary radiotherapy for prostate cancer.

        Exclusion Criteria:

          -  Female patients

          -  Patients with a life expectancy of less than 24 months

          -  with radiological confirmed metastasis

          -  with documented urethral strictures

          -  undergoing chemotherapy

          -  who received brachytherapy

          -  who received chemo-radiotherapy for prostate cancer in the past

          -  previously treated with Bacillus Calmette-Guerin (BCG)

          -  with post-void residual (PVR) &gt; 200ml

          -  with clinical evidence of bladder calculi

          -  with neurogenic bladder or neurologic disease at risk for neurogenic bladder

          -  suffering from any lower urinary infections (UTIs, tuberculosis)

          -  with unstable cardiovascular disease

          -  with Congestive Heart Failure (CHF)

          -  with current nitrate use

          -  with current anticoagulants use (i.e. warfarin, heparin, etc.)

          -  with clinically significant hepatobiliary or renal disease

          -  with history of significant CNS injuries within 6 months

          -  with any other significant disease or disorder which, in the opinion of the
             Investigator, may either put the participants at risk because of participation in the
             trial, or may influence the result of the trial, or the participant's ability to
             participate in the trial
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Massimo LAzzeri, MD</last_name>
    <role>Study Director</role>
    <affiliation>Gruppo di Studio per le Malattie Urogenitali</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Massimo Lazzeri, MD</last_name>
    <phone>+393391072211</phone>
    <email>lazzeri.maximus@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Davide Corradengo</last_name>
    <phone>+393498731588</phone>
    <email>mistic.protocol@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ospedali Careggi</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gianni Vittori</last_name>
    </contact>
    <investigator>
      <last_name>Gianni Vittori, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università &quot;Vita-Salute&quot; San Raffaele</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renzo Colombo</last_name>
    </contact>
    <investigator>
      <last_name>Renzo Colombo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Palermo, Italy</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vincenzo Serretta</last_name>
    </contact>
    <investigator>
      <last_name>Vincenzo Serretta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Cyril and Method University Hospital</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Romancik</last_name>
    </contact>
    <investigator>
      <last_name>Martin Romancik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fakultná nemocnica s poliklinikou</name>
      <address>
        <city>Prešov</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Lunik, MD</last_name>
    </contact>
    <investigator>
      <last_name>Richard Lunik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universidad Autónoma de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Sanguedolce, MD</last_name>
      <email>fsanguedol@fundacio-puigvert.es</email>
    </contact>
    <investigator>
      <last_name>Francesco Sanguedolce</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istanbul University</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bulent Cetinel</last_name>
    </contact>
    <investigator>
      <last_name>Bulent Cetinel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Lips IM, Dehnad H, van Gils CH, Boeken Kruger AE, van der Heide UA, van Vulpen M. High-dose intensity-modulated radiotherapy for prostate cancer using daily fiducial marker-based position verification: acute and late toxicity in 331 patients. Radiat Oncol. 2008 May 21;3:15. doi: 10.1186/1748-717X-3-15.</citation>
    <PMID>18495016</PMID>
  </reference>
  <reference>
    <citation>Pavlidakey PG, MacLennan GT. Radiation cystitis. J Urol. 2009 Sep;182(3):1172-3. doi: 10.1016/j.juro.2009.06.034. Epub 2009 Jul 22.</citation>
    <PMID>19625037</PMID>
  </reference>
  <reference>
    <citation>Smit SG, Heyns CF. Management of radiation cystitis. Nat Rev Urol. 2010 Apr;7(4):206-14. doi: 10.1038/nrurol.2010.23. Epub 2010 Mar 9. Review.</citation>
    <PMID>20212517</PMID>
  </reference>
  <reference>
    <citation>Antonakopoulos GN, Hicks RM, Berry RJ. The subcellular basis of damage to the human urinary bladder induced by irradiation. J Pathol. 1984 Jun;143(2):103-16.</citation>
    <PMID>6737117</PMID>
  </reference>
  <reference>
    <citation>Denham JW, Hauer-Jensen M. The radiotherapeutic injury--a complex 'wound'. Radiother Oncol. 2002 May;63(2):129-45. Review.</citation>
    <PMID>12063002</PMID>
  </reference>
  <reference>
    <citation>Hurst RE. Structure, function, and pathology of proteoglycans and glycosaminoglycans in the urinary tract. World J Urol. 1994;12(1):3-10. Review.</citation>
    <PMID>8012413</PMID>
  </reference>
  <reference>
    <citation>Lazzeri M, Montorsi F. The therapeutic challenge of &quot;chronic cystitis&quot;: search well, work together, and gain results. Eur Urol. 2011 Jul;60(1):78-80. doi: 10.1016/j.eururo.2011.03.039. Epub 2011 Apr 1.</citation>
    <PMID>21474233</PMID>
  </reference>
  <reference>
    <citation>Damiano R, Quarto G, Bava I, Ucciero G, De Domenico R, Palumbo MI, Autorino R. Prevention of recurrent urinary tract infections by intravesical administration of hyaluronic acid and chondroitin sulphate: a placebo-controlled randomised trial. Eur Urol. 2011 Apr;59(4):645-51. doi: 10.1016/j.eururo.2010.12.039. Epub 2011 Jan 18. Erratum in: Eur Urol. 2011 Jul;60(1):193.</citation>
    <PMID>21272992</PMID>
  </reference>
  <reference>
    <citation>De Vita D, Giordano S. Effectiveness of intravesical hyaluronic acid/chondroitin sulfate in recurrent bacterial cystitis: a randomized study. Int Urogynecol J. 2012 Dec;23(12):1707-13. doi: 10.1007/s00192-012-1794-z. Epub 2012 May 22.</citation>
    <PMID>22614285</PMID>
  </reference>
  <reference>
    <citation>Cervigni M, Sommariva M, Porru D, Ostardo E, Tenaglia R, Giammò A, et al. A randomized, open-label, multicentre study of efficacy and safety of intravesical hyaluronic acid and chondroitin sulfate (HA 1.6% and CS 2%) vs dimethyl sulfoxide (DMSO 50%) in women with Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC). Eur Urol Suppl 2014;13(1):e464.</citation>
  </reference>
  <reference>
    <citation>Cervigni M, Van Kerrebroeck PE, Dinis Oliveira P, Tarricone R, Guzman SA. Glycosaminoglycan-Replenishment Therapy: rationale for use and current evidence. EMJ Urol. 2014;1:41-47.</citation>
  </reference>
  <reference>
    <citation>Nordling J. Bladder Pain Syndrome/ Interstitial Cystitis. Update in Europe. International Journal of Urology 2014;21(Supplement S1):A1-A11.</citation>
  </reference>
  <reference>
    <citation>Crew JP, Jephcott CR, Reynard JM. Radiation-induced haemorrhagic cystitis. Eur Urol. 2001 Aug;40(2):111-23. Review.</citation>
    <PMID>11528186</PMID>
  </reference>
  <reference>
    <citation>Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1341-6.</citation>
    <PMID>7713792</PMID>
  </reference>
  <reference>
    <citation>Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994 Nov;47(11):1245-51.</citation>
    <PMID>7722560</PMID>
  </reference>
  <reference>
    <citation>Droller MJ, Saral R, Santos G. Prevention of cyclophosphamide-induced hemorrhagic cystitis. Urology. 1982 Sep;20(3):256-8.</citation>
    <PMID>7123717</PMID>
  </reference>
  <reference>
    <citation>Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000 Dec 20;56(6):899-905.</citation>
    <PMID>11113727</PMID>
  </reference>
  <reference>
    <citation>Hamilton K, Bennett NC, Purdie G, Herst PM. Standardized cranberry capsules for radiation cystitis in prostate cancer patients in New Zealand: a randomized double blinded, placebo controlled pilot study. Support Care Cancer. 2015 Jan;23(1):95-102. doi: 10.1007/s00520-014-2335-8. Epub 2014 Jul 4.</citation>
    <PMID>24993395</PMID>
  </reference>
  <reference>
    <citation>Mottet N, Bastian PJ, Bellmunt J, van den Bergh RCN, Bolla M, van Casteren NJ, et al. Guidelines on Prostate Cancer. Uroweb 2014.</citation>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2018</study_first_submitted>
  <study_first_submitted_qc>April 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2018</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

